Objective: Ticagrelor, cyclopentyl triazolopyrimidine drug, and Clopidogrel, second-generation thienopyridine drug are antiplatelet drugs indicated for the prevention of thrombotic events in patients with acute or chronic coronary syndromes. The aim of this study is to assess efficacy and safety outcomes of ticagrelor treatment versus Clopidogrel treatment in patients with stable coronary artery disease (stable angina) using maximal platelet aggregation percent (MPAP) method and platelet reactivity index percent (PRIP) method.
INTRODUCTION
Clopidogrel is a prodrug that required biotransformation into its active metabolite that irreversibly bound to platelet P 2 Y 12 receptor for the platelet's lifespan (7-10) days and inhibits platelets activation and aggregation [1, 2] . Inhibition of platelets aggregation using thienopyridine drug in addition to aspirin therapy amended the consequences of patients with acute coronary syndromes and patients with stents insertion as compared to patients with aspirin monotherapy [3] .
Some patients after doing percutaneous coronary intervention and using clopidogrel drug with aspirin therapy may have high platelet reactivity (HPR) or may not response to clopidogrel; those patients may expose to higher rates of ischemic complication events [4] .
Ticagrelor, a cyclopentyl triazolopyrimidine compound, is a nonthienopyridine drug and unlike thienopyridine drug, is reversibly bound to platelet P 2 Y 12 receptor. Its inhibit platelet activation and aggregation with a rapid onset of action as compared to clopidogrel [5] .
Many studies found that ticagrelor possess higher antiplatelet potency than clopidogrel, second-generation thienopyridine, and similar antiplatelet potency as prasugrel, third-generation thienopyridine. Therefore, ticagrelor can be used to reduce the risk of subsequent myocardial infarction and stent thrombosis [6, 7] .
As expected, due to the reversible binding of Ticagrelor with P 2 Y 12 receptor this may lead to disperse its antiplatelet effect more rapidly with less bleeding [8] .
The purpose of this crossover study was to assay platelets aggregation using two methods; maximal platelet aggregation percent (MPAP) method and platelet reactivity index percent (PRIP) method with two different treatments ticagrelor treatment or clopidogrel treatment in the same patients with stable angina at different times.
METHODS
Of 60 patients (43 males and 17 females) their ages ranging (50-60) years with stable angina enrolled from Ibn Albitar Center for Cardiac Surgery, only 42 patients (27 males and 15 females), their ages ranging (48±8) years completed the designed period of this crossover study. The reasons for discontinuation-involved patients with normal levels of MPAP who are not need for using antiplatelet drugs, non-cooperative patients, and loss of follow-up.
The crossover study evaluated the same patients at different times in the presence and absence of the therapy under study with the presence of washout period for at least 2 weeks between two treatments.
The Institutional Ethics Committee in each study site approved patient selection and study protocol. Written informed consent was obtained from each patient.
Diagnoses made based on clinical symptoms, clinical biochemical tests (such as cardiac troponin I), and tests such as electrocardiogram, echocardiogram, and cardiac stress test. Exclusion criteria were involved patients with a history of acute coronary syndrome, bleeding, and concomitant therapy that has cytochrome P 3 A inhibitors or Rada inducers, concomitant antithrombotic treatment, hemoglobin (Hb) level <10 g/dl, liver disease, diabetes mellitus, renal failure, heart failure, and patients with neurological disorder such as epilepsy and tumors.
The patients treated with a maintenance dose of clopidogrel (Plavix, France) 75 mg daily for 2 weeks. Then, after a washout period of 2 weeks, the patients treated with a maintenance dose of ticagrelor (Astrazeneca) 90 mg twice daily for another 2 weeks.
Blood samples were collected in vacutainer tubes containing 3.2% sodium citrate, after discarding first 3 ml of free-flowing blood, at baseline (day 0 of treatment), after 2 weeks treatment with clopidogrel and after 2 weeks treatment with ticagrelorin the morning after 2 h of the last dose of the drug intake to measure the MPAP and the PRIP.
The MPAP was assay by measuring the inhibition of ADP (20 μmol/L)-induced platelet aggregation of platelet-rich plasma which expressed as change in light transmittance from baseline, with platelet-poor plasma used as a reference and quantitated by light transmission aggregometry [8] .
Whereas the PRI was assay by using vasodilator-stimulated phosphoprotein (VASP) , platelet VASP-kit, which measured platelet P2Y12 receptor reactivity, and quantified by flow cytometry [9] .
Platelet reactivity was expressed as a PRI and calculated as:
Where MFI is mean fluorescence intensity, PGE1 is prostaglandin E1, and ADP is adenosine diphosphate. The (PRIP) ratio expressed as mean percentage of platelet reactivity and it is inversely correlated with antiplatelet drugs efficiency.
We used the following previously defined cut points of HPR associated with long-term ischemic event occurrence: >59% (20 μmol/L) ADPinduced maximal platelet aggregation [6] and >50% PRI based on the VASP phosphorylation assay [9] .
The primary safety endpoint was defined major bleeding as bleeding with clinically overt evidence or non, associated with a decrease in Hb≥ 5 g/dl, and minor bleeding as bleeding associated with a decrease in Hb of <3 g/dl [7] .
All numerical data stratified as mean±standard deviation with 95% confidence interval. Comparisons of continuous variables were assessed by Student's t-test, p values of 0 <0.05 were regarded to be statistically significant. All statistical analyses were performed using Statistical Package for the Social Sciences version 18.0 for windows.
RESULTS
Baseline clinical data and demographic characteristics of the studied participants displayed in Table 1 . The platelet responsiveness to ADP stimulation, MPAP, after 2 weeks treatment with clopidogrel 75 mg daily was highly appreciably lower as compared with its value at the baseline (before treatment).
Whereas the MPAP in the same patients after 2 weeks washout and after another 2 weeks treatment with ticagrelor 90 mg twice daily was highly appreciably, lower as compared with MPAP value at the baseline or after 2 weeks treatment with clopidogrel 75 mg daily (Table 2 and Fig. 1 ).
As well, the high significant decrease was clarified in PRIP that measured by VASP-phosphorylation after 2 weeks treatment with clopidogrel 75 mg daily as compared with its value at the baseline (before treatment).
In addition, the PRIP in the same patients after 2 weeks washout and after another 2 weeks treatment with ticagrelor 90 mg twice daily was highly significantly decrease as compared with its value at the baseline or after 2 weeks treatment with clopidogrel 75 mg daily (Table 2 and Fig. 1 ).
As noted in Fig. 2 , the bar graph revealed the variations of MPAP and PRIP versus baseline after 2 weeks treatments, high variation achieved Analysis of adverse events showed that two minor bleeding occurred during ticagrelor treatment, and no bleeding occurred during clopidogrel treatment. As well, dyspnea episodes testified in five patients on ticagrelor therapy and three patients on clopidogrel therapy. On continuous treatment, dyspnea commonly ameliorated, especially when its intensity was mild to moderate.
Power analysis for the minimum detectable effect of clopidogrel treatment 75 mg daily or ticagrelor treatment 90 mg twice daily on MPAP and PRIP after 2 weeks of treatments are elucidated in Fig. 3 .
There is 80% probability that a decrease of MPAP by 4.96% with clopidogrel treatment 75 mg daily can be described and by 4.33% with ticagrelor treatment 90 mg twice daily can also be described. As well, there is 80% probability that a decrease of PRIP by 4.74% with clopidogrel treatment 75 mg daily can be sensed and by 4.07% with ticagrelor treatment 90 mg twice daily can also be sensed.
DISCUSSION
The results of this study elucidated that treatment with the reversibly binding platelet P 2 Y 12 , ticagrelor, was greater inhibitor of platelet aggregation than clopidogrel and thereafter reduced major ischemic events by reducing cardiovascular death, myocardial infarction, and stroke without significantly increasing major bleeding, these results are consistent with the PLATO overall results [10, 11] .
Likewise, to the other study [12, 13] , the current study showed that ticagrelor treatment may associate with adverse events such as bradycardia and dyspnea, which may be related to the inhibitory effect of ticagrelor on adenosine reuptake by red blood cells.
Cannon et al. reported that the patients intended for non-invasive management and non-ST elevation coronary artery syndrome, exhibit higher rate of long-term adverse events than did those intended for invasive management [14] . As well, the patients who managed without revascularization usually have more comorbidity, higher risk of bleeding, and inferior outcome than patients who are revascularized [15] .
Cannon et al. revealed that in contrast to clopidogrel treatment, ticagrelor treatment throughout the 1 st week produced an additional ventricular gap that detected by Holter instrument [13] . Many studies reported a link between patients' resistance to clopidogrel and major adverse cardiovascular events (MACE) [16] [17] [18] .
VASP is a critical protein that is involved in the remodeling of the actin cytoskeleton, while in platelets it has a role in regulating adhesive events that are associated with platelet aggregation [19] .
Flow cytometric assessment of VASP phosphorylation and the Verify Now P 2 Y 12 assay has the advantage of measuring P 2 Y 12 function directly, whereas ADP-induced platelet aggregation (light transmission) is influenced by P 2 Y 12 receptor and other receptor (P 2 Y 1 receptor) which activate platelet and promoting platelet aggregation [20] . Some patients after taking antiplatelet drugs will have high posttreatment platelet reactivity which is a better estimate of thrombotic risk than pre-treatment platelet reactivity [21] . Barragan et al. found that inhibition of platelet activity <50% using PRIP is preferred to reduce the risk of stent thrombosis [16] . Other study found that the mortality rate in patients with an acute coronary syndrome has not significantly reduced with clopidogrel treatment [2] , or with glycoprotein IIb/IIIa inhibitors treatment [22] .
Many studies reported various limitations of clopidogrel therapy which include variable and irreversible platelet inhibition, slow onset of action, modest level of platelet inhibition, and considerably proportion of patients exhibiting limited response [23] . However, numerous strategies have been used to improve responses to clopidogrel, including increasing dosages or adding other agents [24] .
The values of international normalization ratio (INR) in some patients were falsely impaired and increased due to the interference of antiphospholipid antibody with thromboplastins [25] . In addition, some drugs can form a complex with platelets and trigger immunemediated thrombocytopenia that enhances platelets destruction and suppresses platelets levels [26] .
CONCLUSION
Ticagrelor a reversibly platelet P 2 Y 12 receptor binding oral drug has more intense platelets inhibition than Clopidogrel, and so reduces the risks of ischemic events and mortality without increasing major bleeding, and it may use to overcomes the non-responsiveness to clopidogrel.
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